TRRASS Think Tank

  Introduction SKF India is one of the most advanced engineering and motion-technology companies in India. Its precision bearings, seals, lubrication systems and condition-monitoring solutions power critical sectors such as Electric Vehicles, Railways, Wind Energy, Industrial Automation, Passenger Vehicles and Commercial Vehicles . The company’s financial quality is exceptional: Zero debt Strong cash reserves ROCE consistently above 27–29% High free cash flow Global SKF R&D support Sticky OEM relationships In FY25, SKF restructured its automotive and industrial operations for strategic clarity. Because of this accounting change, the share price adjusted from around ₹5,000 to ~₹2,300 , reflecting value split between two entities — not a business decline . All manufacturing, customers, cash reserves and R&D access remain intact. SKF continues to operate as a stable high-quality compounding business. Business Segments Automotive Division (≈40% rev...

  A High-Conviction Deep Dive — TRRASS Think Tank The stock market loves noise. But multi-baggers? They are usually born in silence. Some companies quietly build capacity, sharpen their product lines, fix their balance sheets, and strengthen their distribution… until one day, the market wakes up and says: “Wait… when did this stock get so strong?” Themis Medicare is exactly at that stage. At a CMP of ~₹102, the stock looks forgotten. But under the hood, the business is entering its most powerful transformation phase in years. This is not hype. This is not speculation. This is the kind of setup long-term investors dream of. Let’s break the entire story down — clean, sharp, and brutally honest. 🌱 1. What Exactly Is Happening at Themis? The more you study this company’s quarterly updates, the more one thing becomes clear: 👉 Themis Medicare is shifting from a small generic player to a focused, hospital-centric formulations company. This shift is BIG. And it's the same...

  Anthem Biosciences, trading near ₹660 , is rapidly emerging as one of India’s most promising early-stage CRDMO platforms. With global-scale capabilities, zero debt, high margins, and strong demand in complex chemistry and biology, the company has positioned itself in one of the fastest-growing pharma outsourcing segments. This analysis explores whether Anthem has the long-term potential to deliver 10X–50X returns, supported by its CRDMO model, global clientele, expansion roadmap, and molecule pipeline. 🔬 What Is CRDMO? CRDMO (Contract Research, Development & Manufacturing Organization) integrates three major verticals of the drug development lifecycle: 1️⃣ Research (CRO) – Drug discovery – Chemistry & biology studies – Toxicology and experimentation 2️⃣ Development (CDO) – Kilo lab – Scale-up – Pilot batches – Process optimisation 3️⃣ Manufacturing (CMO) – Commercial API production – Peptide manufacturing – Fermentation products – High-potent oncology AP...

The Indian tobacco & FMCG sector has always remained a powerhouse of cash generation. Among all companies in this space, ITC and Godfrey Phillips India (GPI) stand out as the two strongest contenders. Both companies deliver solid profits, strong cash flow, and consistent dividends — but their long-term potential is very different. This blog presents a clean, professional, and objective comparison between the two companies, along with a 10-year multibagger evaluation for each. 1. Business Model Comparison ITC Ltd – A Diversified Powerhouse ITC operates across multiple segments: Cigarettes FMCG (Aashirvaad, Sunfeast, Yippee, Fiama, Savlon) Hotels Paper & Packaging Agri-business Why this matters: Diversification protects ITC from regulatory shocks in cigarettes and creates long-term compounding potential. Godfrey Phillips – A Focused High-Margin Tobacco Company GPI’s business is sharply focused: 99% revenue from cigarettes and tobacco Strong ...